# Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma

> **NCT06957431** · PHASE1 · RECRUITING · sponsor: **Washington University School of Medicine** · enrollment: 18 (estimated)

## Conditions studied

- Advanced Leiomyosarcoma
- Adipocytic Sarcoma
- Advanced Liposarcoma

## Interventions

- **DRUG:** Zanzalintinib
- **DRUG:** Eribulin

## Key facts

- **NCT ID:** NCT06957431
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-22
- **Primary completion:** 2028-11-30
- **Final completion:** 2033-10-31
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2025-10-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06957431

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06957431, "Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT06957431. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*